ACE-inhibitor of proven efficacy – benazepril Review article
Article Sidebar
Main Article Content
Abstract
Acknowledged for many years as one of the safest and most effective ACE-inhibitors in the treatment of arterial hypertension, benazepril owes its particular results to certain specific qualities. High bioavailability, extended duration of action, double metabolic elimination route and good safety are the winning attributes of benazepril, which can be safely administered even in elderly patients or those suffering from kidney disease. The results of the Chinese research demonstrate that benazepril can be administered in total safety at full doses even in patients with stage 4 renal insufficiency. The study also shows that benazepril is effective even when renal insufficiency progresses and levels of creatinine continue to increase.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Smith W.M., Gomez H.J.: The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol. 1991; 14 (supl. 4): IV79-IV82.
3. Le Feuvre C., Francillon A., Renucci J.F. et al.: [Comparison of clinical and ambulatory measurements of blood pressure with benazepril alone or combined with hydrochlorothiazide in hypertension]. Therapie 1996; 51(1): 27-34.
4. Haziza H.M., Francillon A., Mottier D., Heintzmann F., Serrurier D.: Activité antihypertensive et facteurs prédictifs d’efficacité du bénazépril dans l’hypertension artérielle légère à modérée. Ann. Cardiol. Angeiol. 1998; 47: 33-41.
5. Moser M., Abraham P.A., Bennett W.M. et al.: The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study. Clin. Pharmacol. Ther. 1991; 49: 322-9.
6. Farmakologia inhibitorów konwertazy angiotensyny. W: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Januszewicz A., Januszewicz W., Rużyłło W. (red.). Medycyna Praktyczna, Kraków 2005: 89-106.
7. Rutkowski P., Tylicki L., Renke M. et al.: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 2004; 43: 260.
8. De Cesaris R., Ranieri G., Andriani A., Lamontanara G.: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with Diabetes. Clin. Pharm. Therap. 1996; 60: 472-478.
9. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334: 939.
10. Hou F.F., Zhang X., Zhang G.H. et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. New Engl. J. Med. 2006; 354: 131-140.
11. Whalen J.J.: Definition of The effective dose of the converting enzyme inhibtor benazepril. Am. Heart J. 1989; 117: 728-734.
12. Balfour J.A., Goa K.L.: Benazepril: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42: 511-539.